SYSMEX UK LIMITED

• ◆

  1 PSC ceased in last 24 months

  Significant control changed hands — see the Ownership section.

1. SYSMEX UK LIMITED 1995-05-25 → present
2. TOA MEDICAL ELECTRONICS (U.K.) LIMITED 1991-05-22 → 1995-05-25
3. KEEPMERGE LIMITED 1991-04-05 → 1991-05-22

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 101

Reporting scope

Standalone (parent only)

Auditor

Deloitte LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The financial position of Sysmex UK Limited remains strong, with its high liquidity position and no external borrowings. The directors believe that Sysmex UK Limited, with existing long-term contracts and strong market position, will well placed to manage its business risks successfully despite the current uncertain economic outlook. Accordingly, they continue to adopt the going concern basis in preparing the annual report and accounts.”

Significant events

• “Sysmex UK reported a significant increase in turnover for fiscal year 2024/25, with a 4.5% growth in external sales, driven by contract refreshes in the UK.”
• “The UK operation's turnover grew by 8.1% to £75 million in external sales, an increase of £5.6 million, primarily due to demand for Haematology instrumentation and contract extensions.”
• “3rd party products under managed service contract increased by 13.9%.”
• “Irish business turnover decreased by 13.4% to €12.2 million due to a large installation reported in 2024 and a reduction in 3rd party business of €1.3 million as Sysmex is no longer the primary managed service provider.”
• “Urine diagnostics business in the UK showed good growth of 39.3%.”
• “Company was awarded the prestigious Longitude Prize for AMR in 2024.”
• “Company continues to offer the new XR series of Haematology analysers, successor to the XN series, with enhancements for workload efficiency, throughput, and automation.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

2

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +4.5%

  £81,628,130 → £85,293,938

• Cash

  +21.3%

  £4,110,158 → £4,987,101

• Net assets

  +7.5%

  £36,186,902 → £38,895,963

• Employees

  +6%

  200 → 212

• Operating profit

  +34.6%

  £2,705,688 → £3,643,119

• Profit before tax

  +32.1%

  £2,683,634 → £3,544,210

• Wages

  +11.9%

  £14,927,388 → £16,710,302

Each % is (latest − prior) ÷ |prior| for the line item as filed. Periods don't have to be exactly 12 months apart — a long or short period (typical around incorporation or year-end changes) will distort the comparison. Lines a company doesn't report are omitted. About these numbers